Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Samsung Bioepis Also Faces 2029 Wait For US Etanercept Biosimilar

New Jersey Court Enters Permanent Injunction Against Korean Firm

Executive Summary

Samsung Bioepis’ etanercept biosimilar, freely available in Europe, will not be sold in the US until patent expiry in 2029 following action by a US district court.

You may also be interested in...



Induced Infringement And Price Fixing Among Legal Headlines In 2021

In 2021, courts across the US and beyond continued to weigh key patent litigation fights, alongside the thorny issue of induced infringement via label carve outs and controversial charges for generic price fixing.

How Samsung Bioepis Is Laying A Path For Ophthalmic Biosimilars

With the first approved rival to Lucentis in both the EU and US, Samsung Bioepis is laying the groundwork for biosimilars to break into ophthalmology ahead of launching its Byooviz version of ranibizumab, explains vice-president of commercial strategy Josh Lee.

Samsung Bioepis Moves Forward With Soliris Rival

Samsung Bioepis has confirmed completion of its Phase III trial for a proposed biosimilar to Soliris, putting it ahead of rival developer Amgen which has negotiated a date-certain US launch.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB151448

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel